Phase 3 N=61 Cholinesterase Inhibitor Discontinuation
Dementia
Primary: Successful Completion — 20; 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=407 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Acute Pain
Primary: Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo. — 47; 61; 56; 37 Participants
Phase 3 N=748 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 31.38; 29.47 Months — p=0.4358
Phase 3 N=255 Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Relapsed/Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) — 2.6; 1.7 months — p==0.0054
Phase 3 N=4,514 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
Influenza, Human
Primary: Primary Efficacy: First Occurrence of Either RT-PCR- or Culture-confirmed Influenza (Time-to-event Analyses) Due to Any Influenza Type A or B Strain Regardless of…
Phase 3 N=237 BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 153; 82; 77; 44 Participants
Phase 3 N=312 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236
Phase 3 N=24 Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
Pancreatic Cancer · Unresectable Biliary-pancreatic Malignancies
Primary: Rate of Failure
Phase 3 N=396 BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Hypertension, Pulmonary
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 229; 108; 56; 138 Participants
Phase 3 N=298 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases
Bone Metastases
Primary: Radiation-induced Pain Flare Incidence — 39; 53 Participants — p=0.05
Phase 3 N=326 Treatment of Patients With Nocturia (Non-PK Study)
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
Phase 3 N=4,994 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
Transfusion · Age of Blood
Primary: Mortality at Day 90 — 610; 594; 264; 259 participants
Phase 3 N=194 The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Chronic Kidney Disease
Primary: Number of Participants in Each Dose Arm Prescribed (i) Full Randomized Sodium Bicarbonate Dose at End of 28 Weeks & (ii) at Least 25% of Randomized Sodium Bicarbonate…
Phase 3 N=172 Study of T-PRED(TM) Compared to Pred Forte(R) II
Cataract
Primary: Means Aqueous Humor Prednisolone Acetate Concentration — 100.02; 131.65 ng/mL
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001